Neurogene Past Earnings Performance
Past criteria checks 2/6
There is insufficient data on Neurogene's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -19.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How Neurogene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | 14 | 11 | 0 |
| 30 Sep 23 | 0 | -51 | 11 | 47 |
| 30 Jun 23 | 0 | -49 | 9 | 42 |
| 31 Mar 23 | 0 | -52 | 9 | 44 |
| 31 Dec 22 | 0 | -55 | 9 | 0 |
Quality Earnings: NGNE has a large one-off gain of $16.4M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: NGNE became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NGNE has become profitable over the past 5 years.
Accelerating Growth: NGNE has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NGNE has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: NGNE's Return on Equity (-19.5%) is considered low.